LRMR
Larimar Therapeutics, Inc.BS score 22.8LOWPHASE2 · mkt cap $528.8M · rev ttm $0
drug hypothesis
CTI-1601 modulates Frataxin to treat Friedreich's Ataxia.
moa:Frataxin replacement therapy - delivers functional frataxin protein to increase frataxin levels in patients with Friedreich's Ataxia, a rare genetic disorder characterized by frataxin deficiency.
score breakdown
trial design15
base rate disconnect12
language red flags60
composite22.8
valuation analysis
market cap$528.8M
revenue ttm$0
phasePHASE2
historical base rate25%
disconnect ratio0.4x
lead trialNCT04176991
meta
cik0001374690
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1 randomized, quadruple-blind, placebo-controlled, single ascending dose study in 28 subjects with Friedreich's Ataxia. Started 2019-12-11, primary completion 2020-10-31.
primary endpoint:Number of Participants with Treatment-Emergent Adverse Events (Through study completion, an average of 70 days)
claimed differentiation
Not explicitly stated in provided filing data
language red flags
- Limited information provided - only clinical trial data present, no detailed SEC filing business section text visible
- No explicit differentiation claims or risk disclosures found in available data
- Cannot assess hedging language or promotional claims without full SEC filing text